Gujrathi leaving as Gossamer CEO; plus Spark, Atlas, Flagship, Talaris

Sheila Gujrathi is departing Gossamer Bio Inc. (NASDAQ:GOSS) as president and CEO, roles in which she will be succeeded by Chairman Faheem Hasnain.

Michael Retterath joined gene therapy play Spark Therapeutics Inc., which Roche (SIX:ROG; OTCQX:RHHBY) acquired last year, as CSO. Retterath joins the company from Bain & Co., where he has served as a partner in the healthcare practice for a decade...